Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MAGED2 mediates AKT pathway regulates the biological function of glioblastoma

ABSTRACT: Glioma is the most common primary intracranial malignant tumor in the brain, and according to the fifth edition of the World Health Organization (WHO) classification, glioblastoma multiforme (GBM) is the most malignant grade IV glioma.The median survival period of GBM patients is only 15 months, and the 5-year survival rate is less than 5%. At present, the treatment of glioma is mainly to achieve maximal safe resectionby surgery by surgery, combined with radiotherapy and chemotherapy, to prolong the patient's survival as much as possible.However, due to the high heterogeneity and invasiveness of glioma, it is easy to relapse after surgery.In addition, the clincal efficacy is not ideal because of the blood-brain barrier and drug resistance. Therefore, it is urgent to find novel targets for glioma treatment. MAGE-D2 (MAGE Family Member D2) is a member of the melanoma-associated antigen type II subfamily. MAGE-D2 has been identified as being critical for transcriptional regulation, epigenetic alteration, cell development and differentiation,and is involved in the regulation of cell cycle. Furthermore, numerous studies have shown that MAGE-D2 is a tumor-specific antigen that plays an important role in tumor progression and metastasis, including hepatocellular carcinoma, gastric cancer, and lymphoma. However, the precise function and mechanism of MAGE-D2 in glioma is still unknown.

ORGANISM(S): Homo sapiens

PROVIDER: GSE261882 | GEO | 2026/03/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq analysis of mouse brain endothelial cells and glioma endothelial cells

Project description:Glioblastoma multiforme (GBM) is a highly aggressive and vascularized malignant brain tumor. Anti-VEGF therapy is widely used for the treatment of GBM, however it has shown only minor impact on patient survival. Thus, more precise molecular mechanisms for glioma angiogenesis are needed for the advance in the treatment of GBM. Here, we investigated gene expression profile of brain endothelial cells and glioma endothelial cells using RNA sequencing to validated special molecular features of glioma endothelial cells.

2017-11-24 | GSE90459 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [HK-374_bulkRNA-seq]

Project description:Despite advances in surgery and radiotherapy, glioblastoma (GBM) remains the deadliest adult brain cancer with unacceptable low median survival rates. Targeted therapies and biologics have failed to improve outcome and the standard-of-care against GBM has not changed in two decades. GBM, like many solid tumors are thought to be organized hierarchically with a small number of radiation- and chemotherapy-resistant glioma stem cells (GSCs) producing more differentiated progeny and can repopulate tumors after sublethal treatment.In this study we sought to develop novel compounds that cross the blood-brain barrier (BBB), target existing GSCs and interfere with glioma cell plasticity to prevent the induction of GSCs in response to irradiation. We show that novel urea compounds target existing GSCs, prevent the radiation-induced conversion of non-stem glioma cells into GSCs and prolong the median survival in mouse models of GBM with minimal normal tissue toxicity.

2025-04-26 | GSE295095 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [scRNAseq_MXC-017_374_in_vivo]

2025-04-23 | GSE295066 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [HK-217_scRNAseq_MXC-017_in_vitro]

2025-04-22 | GSE294961 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [HK-374]

2025-04-17 | GSE294831 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [HK-244_scRNAseq_MXC-017_in_vitro]

2025-04-17 | GSE294815 | GEO

Design and Biological Activity of a Novel Urea Compound Against Glioblastoma [HK-390_scRNA-seq]

2025-04-26 | GSE295096 | GEO

Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting

Project description:Glioblastoma (GBM) is the most frequent and malignant brain tumor with an overall survival of only 14.6 months. Although these tumors are treated with surgery, radiation and chemotherapy recurrence is inevitable. A critical population of tumor cells in terms of therapy, the so-called cancer stem cells (CSCs), has been identified in gliomas and many other cancers. These tumor cells have a stem cell-like phenotype and are suggested to be responsible for tumor growth, chemo- and radio-resistance as well as recurrence. However, functional evidence for migrating glioma cells having a stem cell-like phenotype is currently lacking.

2016-12-22 | GSE76018 | GEO

Analysis of microRNA expression profile in malignant glioma tissues

Project description:Malignant gliomas represent the most devastating group of brain tumors in adults, among which glioblastoma multiforme (GBM) exhibits the highest malignancy rate. Despite combined modality treatment, GBM recurs and is invariably fatal. A further insight into molecular background of gliomagenesis is required to improve patient outcome. The first aim of this study was to gain broad information on miRNA expression pattern in malignant gliomas, mainly GBM. We investigated the global miRNA profile of malignant glioma tissues by means of miRNA microarrays, deep sequencing and meta-analysis. We selected miRNAs the most frequently deregulated in glioblastoma tissues as well as peritumoral brain areas in comparison to normal human brain. We found candidate miRNAs contributing to progression from gliomas grade III to gliomas grade IV. The meta-analysis of miRNA profiling studies in GBM tissues summarizes the past and recent advances in an investigation of miRNA signature in GBM versus noncancerous human brain and provides a comprehensive overview. We proposed a set of 35 miRNAs which expression is the most frequently deregulated in GBM patients and 30 miRNA candidates recognized as novel GBM biomarkers. miRNA expression profile in the adult malignant gliomas, glioma peritumoral tissues and normal human brain.

2014-09-26 | E-GEOD-61710 | biostudies-arrayexpress

SCOPE-seq Analysis of Intra-operative Labeling Specificity of 5-ALA for Glioblastoma

Project description:Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor, and surgical resection is a key part of the standard-of-care. In fluorescence-guided surgery (FGS), fluorophores are used to differentiate tumor tissue from surrounding normal brain. The heme synthesis pathway converts 5-aminolevulinic acid (5-ALA), a fluorogenic substrate, to the fluorophore protoporphyrin IX (PpIX). The resulting fluorescence is thought to be specific to transformed glioma cells, but this specificity has not been examined at single cell level. Here, we performed paired single cell imaging and RNA sequencing of individual cells (SCOPE-seq2) on human GBM surgical specimens with visible PpIX fluorescence from patients who received 5-ALA prior to surgery. SCOPE-seq2 allows us to simultaneously measure PpIX fluorescence by imaging and unambiguously identify transformed glioma cells from single-cell RNA-seq (scRNA-seq). We observed that 5-ALA treatment results in labeling that is not specific to transformed tumor cells. In cell culture experiments, we further demonstrated untransformed cells can be labeled by 5-ALA directly or by PpIX secreted from surrounding transformed cells. In acute slice cultures from mouse glioma models, we showed that 5-ALA preferably labels GBM tumor tissue over non-neoplastic brain tissue at bulk level, and that this contrast is not due to blood-brain-barrier disruption. Taken together, our findings support the use of 5-ALA as an indicator of GBM tissue, but not as a specific marker of transformed glioma cells.

2022-11-30 | GSE218331 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data